TUBA4A downregulation as observed in ALS <i>post-mortem</i> motor cortex causes ALS-related abnormalities in zebrafish.

"Conflict of interest ACL serves on the Advisory Board of Roche Pharma (Basel, Switserland) and Biogen (Cambridge, MA, USA), and on the data and safety monitoring board of Zeneus pharma (Bray, UK). ACL received consulting fees from AB Science (Paris, France), Desitin (Buckinghamshire, UK), Novartis (Basel, Switserland) and Teva (Jerusalem, Israel). PVD participated in advisory board meetings of Biogen (Cambridge, MA, USA), Cytokinetics (San Francisco, CA, USA), Ferrer (Barcelona, Spain), UCB (Brussels, Belgium), Argenx (Ghent, Belgium), Muna Therapeutics (Copenhagen, Denmark), Alector (San Francisco, CA, USA), Augustine Therapeutics (Leuven, Belgium), Alexion Therapeutics (Boston, MA, USA) and QurAlis (Cambridge, MA, USA). DRT received speaker honorary or travel reimbursement from Biogen (USA), UCB (Brussels, Belgium), and collaborated with Novartis Pharma AG (Basel, Switzerland), Probiodrug [Halle (Saale), Germany, GE Healthcare Amersham, UK], and Janssen Pharmaceutical Companies (Beerse, Belgium). LVDB is scientific founder and head of the Scientific Advisory Board of Augustine Therapeutics (Leuven, Belgium). The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript, or in the decision to publish the results."

"The author(s) declare financial support was received for the research, authorship, and/or publication of the article. EVS is funded by an SB Fellowship of the Research Foundation–Flanders (FWO) (1S46219N). DS is funded by a fundamental FWO fellowship (11D4523N). EB is funded by a fundamental FWO Fellowship (1145619N). VB is funded by a postdoctoral FWO Fellowship (12Y9120N). PVD holds a senior clinical investigatorship of FWO and is supported by the E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders, the KU Leuven ALS funds “Een hart voor ALS,” “Laeversfonds voor ALS onderzoek,” and “Valéry Perrier Race against ALS fund.” LVDB is supported by the Generet Award for rare diseases 2022. PVD and LVDB are supported by the ALS Liga Belgium. PVD, LVDB and DRT received C1-internal funds from KU Leuven (C14-17-107, C14/22/132). DRT is additionally funded by the FWO-Odysseus grant G0F8516N and FWO grant G065721N."